VERICEL CORPORATION Expense Breakdown
No Expense Breakdown for VCEL on this site yet.
- 2026-06-30: Single Reportable $20.02M.
- 2025-06-30: Single Reportable $19.61M.
Source checked: the stored Expense Breakdown page for VCEL.
Expenses by product
General and Administrative Expense: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $20.02M |
| 2025-06-30 | $19.61M |
Selling and Marketing Expense: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $28.45M |
| 2025-06-30 | $22.30M |
Selling, General and Administrative Expense: each quarter (3 month)
| Quarter end | Single Reportable |
|---|---|
| 2026-06-30 | $48.48M |
| 2025-06-30 | $41.91M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |